Urban elites drive GLP-1 weight loss boom; distribution deals, price cuts can change script

weight loss

The GLP-1 drugs that powered the weight loss market, led by semaglutide (Wegovy) and tirzepatide (Mounjaro), has crossed Rs 1,000-crore sales within a short time.

Mounjaro (tirzepatide) was launched in India in March 2025, while Wegovy (semaglutide) followed in late June 2025.Yet, their usage remains concentrated in metros and ccccaffluent states, highlighting a significant access gap.

GLP-1 drugs are a class of medications that have gained significant attention for their use in treating Type 2 diabetes and obesity.

According to Pharmatrac, Mumbai’s metropolitan region alone accounts for 16 percent of national GLP-1 sales, growing almost three-fold year on year (YoY), while Maharashtra, as a whole, contributes 24 percent to the market, despite representing just 9 percent of India’s population. Delhi and Bengaluru have around 12 percent and 5 percent market share, respectively.

Mumbai, Delhi and Bengaluru alone account for one-third of GLP-1 sales.

Even in Mumbai, the more prosperous neighbourhoods are driving the sales. Pharmatrac’s pin code secondary sales show saliency clusters in Juhu–Andheri West–Jogeshwari West, Santacruz–BKC, Colaba–Grant Road–August Kranti Maidan, Worli–Dadar–Wadala, and Goregaon/Malad/Kandivali West, neighbourhoods with higher income density and a concentration of celebrity clientele and specialised weight loss clinics. By contrast, contribution from lower income localities is markedly smaller.

Uttar Pradesh—home to 17 percent of the national population— has seen only 8 percent of GLP-1 sales. Bihar and Jharkhand, with 12 percent population share, barely registered at 1 percent. The obesity prevalence hovers around 40 percent nationally and exceeds 45 percent in metros like Delhi and Bengaluru. It hasn’t translated into proportional uptake in non-urban regions.

Affordability, accessibility and awareness 

Analysts cite affordability, accessibility and awareness as key reasons for the weight loss drugs' limited penetration.

Companies are trying to address these issues through price cuts, building awareness, and entering into distribution partnerships with Indian companies to expand their reach.

Until recently, Wegovy’s monthly cost exceeded Rs 16,000 per syringe, while Mounjaro pens were priced upwards of Rs 20,000.

A mid-November steep price cut for Wegovy triggered a 70 percent spike in consumption, proving price elasticity is real. But even after reductions, therapy costs remain prohibitive for middle-income households, especially when paired with diagnostics and lifestyle programmes that urban providers bundle for safety and efficacy. In India, expenditure on medicines is largely met out-of-pocket, while weight loss therapies are still seen as a discretionary spends.

Distribution deals with Indian drugmakers 

That could change. Eli Lilly and Novo Nordisk, which are largely metro heavy presence, have entered into distribution pacts with Indian drugmakers to expand accessibility beyond metro cities. For instance, Lilly entered into a partnership with Cipla, giving the latter rights to distribute and promote its second tirzepatide brand Yurpeak. Lilly will manufacture and supply Yurpeak to Cipla, and the price will be the same as Mounjaro. A similar agreement is struck by Novo Nordisk with Emcure to launch second brand - Poviztra (semaglutide 2.4 mg).

"Cipla’s strategic priority is to make it available across India, including regions beyond metro cities, leveraging its strong distribution network and deep market insights to drive greater nationwide reach and accessibility," the company said in a statement on December 10, 2025, on the launch of Yurpeak.

There could be more such distribution partnerships, ahead of the expected entry of Indian companies with semaglutide generics, post March 2026. Analysts say generics could cost by 50–70 percent cheaper, opening up Tier-2 and Tier-3 markets where obesity prevalence is rising but treatment penetration is negligible.

“Urban India has been the early adopter because of affordability and access to structured programmes,” said Sheetal Sapale, President – Marketing at Pharmatrack. “But the moment pricing drops and distribution widens through local alliances, we will see a massive shift in demand from metros to smaller towns.”